Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.5850 (-2.52%) ($6.5850 - $6.5850) on Mon. Aug. 29, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.18% (three month average) | RSI | 45 | Latest Price | $6.5850(-2.52%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.7% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) GDXJ(93%) XBI(92%) ARKK(91%) EWG(89%) IWF(87%) | Factors Impacting TGTX price | TGTX will decline at least -3.59% in a week (0% probabilities). UUP(-62%) TBT(-31%) USO(-23%) XOP(11%) XLE(16%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.59% (StdDev 7.18%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.16 | 5 Day Moving Average | $7.05(-6.6%) | 10 Day Moving Average | $7.13(-7.64%) | 20 Day Moving Average | $7.16(-8.03%) | To recent high | -21.8% | To recent low | 76.3% | Market Cap | $834m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |